Creative Medical Technology Holdings, Inc. Common Stock (CELZ) Stock Price

CELZStock

$1.24−62.07%52W

Market Cap$8.17M

P/E—

PEG Ratio—

Div yield—

Beta1.89

CELZ Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-48.87%

Price vs S&P 500 (4W)61.26%

VGM Score25.15

Book Value / Share (Quarterly)$1.65

P/TBV (Annual)0.71x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)-59.45%

Cash Flow / Share (Quarterly)$-1.51

Price vs S&P 500 (YTD)-50.22%

Gross Margin (TTM)63.50%

Net Profit Margin (TTM)-58762.83%

EPS (TTM)$-2.04

10-Day Avg Trading Volume1.82M

EPS Excl Extra (TTM)$-2.04

Revenue Growth (5Y)-48.14%

EPS (Annual)$-2.52

ROI (Annual)-79.78%

Gross Margin (Annual)63.50%

Net Profit Margin (5Y Avg)-39703.89%

Cash / Share (Quarterly)$1.58

Revenue Growth QoQ (YoY)0.00%

ROA (Last FY)-76.77%

Revenue Growth TTM (YoY)-78.57%

EBITD / Share (TTM)$-2.02

ROE (5Y Avg)-18.70%

Operating Margin (TTM)-60104.33%

Cash Flow / Share (Annual)$-1.58

P/B Ratio1.34x

P/B Ratio (Quarterly)1.25x

Net Income / Employee (Annual)$-1,498,800

EV / Revenue (TTM)408.60x

Net Interest Coverage (TTM)-0.03x

ROA (TTM)-84.71%

EPS Incl Extra (Annual)$-2.52

Current Ratio (Annual)25.97x

Quick Ratio (Quarterly)19.35x

3-Month Avg Trading Volume6.78M

52-Week Price Return-62.07%

Revenue / Employee (TTM)$800

Tangible BV / Share (Quarterly)$1.55

P/S Ratio (Annual)1362.46x

Asset Turnover (Annual)0.00x

52-Week High$6.25

Operating Margin (5Y Avg)-46248.59%

EPS Excl Extra (Annual)$-2.52

26-Week Price Return-37.63%

Quick Ratio (Annual)25.49x

13-Week Price Return-47.39%

Total Debt / Equity (Annual)0.00x

Current Ratio (Quarterly)19.69x

Enterprise Value$2.45M

Revenue / Share Growth (5Y)-75.20%

Asset Turnover (TTM)0.00x

Revenue / Employee (Annual)$1,500

Inventory Turnover (Annual)2.00x

Pretax Margin (Annual)-99916.83%

Cash / Share (Annual)$1.95

3-Month Return Std Dev255.10%

Gross Margin (5Y Avg)58.92%

Net Income / Employee (TTM)$-1,440,500

ROE (Last FY)-79.78%

Net Interest Coverage (Annual)-0.35x

EPS Basic Excl Extra (Annual)$-2.52

Receivables Turnover (TTM)34.00x

Total Debt / Equity (Quarterly)0.00x

EPS Incl Extra (TTM)$-2.04

Receivables Turnover (Annual)32.00x

ROI (TTM)-88.50%

P/S Ratio (TTM)1362.46x

Pretax Margin (5Y Avg)-39703.89%

Revenue / Share (Annual)$0.00

Tangible BV / Share (Annual)$1.92

Price vs S&P 500 (52W)-80.38%

Year-to-Date Return-38.27%

5-Day Price Return12.04%

EPS Normalized (Annual)$-2.52

ROA (5Y Avg)-18.17%

Net Profit Margin (Annual)-99916.83%

Month-to-Date Return82.23%

Cash Flow / Share (TTM)$-6.88

EBITD / Share (Annual)$-2.53

Operating Margin (Annual)-102380.17%

LT Debt / Equity (Annual)0.00x

ROI (5Y Avg)-18.70%

LT Debt / Equity (Quarterly)0.00x

EPS Basic Excl Extra (TTM)$-2.04

P/TBV (Quarterly)1.33x

P/B Ratio (Annual)0.67x

Inventory Turnover (TTM)2.00x

Pretax Margin (TTM)-58762.83%

Book Value / Share (Annual)$2.03

Price vs S&P 500 (13W)-50.19%

Beta1.89x

Revenue / Share (TTM)$0.00

ROE (TTM)-88.50%

52-Week Low$0.62

vGradeD

gGradeF

mGradeD

vgmGradeD

CELZ Earnings Surprise History

Q2 25-0.48est. -0.63

Q3 25-0.48est. -0.48

Q4 25-0.80est. -0.37

Q1 26-0.38est. -0.39

Q2 26-0.41est. -0.39

CELZ Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.14

Industry Peers — Biological Products(183)

Symbol	Value Score	Growth Score	Momentum Score	Price
CELZCreative Medical Technology Holdings, Inc. Common Stock	D	F	D	$1.24
AMGNAmgen Inc	C	C	B	$442.24
GILDGilead Sciences Inc	C	B	B	$148.77
MRNAModerna, Inc. Common Stock	D	C	A	$158.83
ARGXargenx SE American Depositary Shares	D	A	B	$1019.49
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$211.38
BIIBBiogen Inc. Common Stock	C	D	B	$220.77
BNTXBioNTech SE American Depositary Share	C	C	B	$114.05
NBIXNeurocrine Biosciences Inc	C	B	C	$153.37
EXELExelixis Inc	C	B	B	$56.72
HALOHalozyme Therapeutics, Inc.	C	B	A	$109.32
TECHBio-Techne Corp.	D	C	B	$72.33
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$356.19
KYMRKymera Therapeutics, Inc. Common Stock	D	B	B	$126.64
RGENRepligen Corp	D	C	A	$181.69
APGEApogee Therapeutics, Inc. Common Stock	—	—	A	$134.85
TWSTTwist Bioscience Corporation Common Stock	D	B	A	$151.42
PCVXVaxcyte, Inc. Common Stock	—	—	B	$61.09
QGENQIAGEN N.V.	C	C	C	$43.65
IMVTImmunovant, Inc. Common Stock	—	—	B	$43.50
IBRXImmunityBio, Inc. Common Stock	F	A	C	$8.19
SRRKScholar Rock Holding Corporation Common Stock	F	—	B	$58.25
CGONCG Oncology, Inc. Common stock	F	A	A	$78.95
CRSPCRISPR Therapeutics AG	D	B	B	$60.90
RLAYRelay Therapeutics, Inc. Common Stock	F	D	A	$20.57
ADPTAdaptive Biotechnologies Corporation Common Stock	D	B	A	$26.25
DNLIDenali Therapeutics Inc. Common Stock	F	—	B	$24.93
IOVAIovance Biotherapeutics, Inc. Common Stock	C	B	A	$8.44
BEAMBeam Therapeutics Inc. Common Stock	C	B	B	$31.03
TARSTarsus Pharmaceuticals, Inc. Common Stock	D	A	B	$71.45
BCRXBioCryst Pharmaceuticals Inc	B	A	B	$9.83
KODKodiak Sciences Inc Common Stock	—	—	B	$39.46
COAGHemab Therapeutics Holdings, Inc. Common Stock	—	—	B	$49.65
MESOMesoblast Limited American Depositary Shares	D	B	C	$17.19
VCELVericel Corporation	D	B	C	$43.22
ADMAADMA Biologics, Inc.	C	C	C	$9.72
TSHATaysha Gene Therapies, Inc. Common Stock	F	B	B	$6.20
IMCRImmunocore Holdings plc American Depositary Shares	D	B	B	$37.40
RXRXRecursion Pharmaceuticals, Inc. Class A Common Stock	D	C	C	$3.56
VIRVir Biotechnology, Inc. Common Stock	B	B	B	$10.71
INBXInhibrx Biosciences, Inc. Common Stock	D	C	B	$122.72
ALVOAlvotech Ordinary Shares	C	D	B	$5.05
MAZEMaze Therapeutics, Inc. Common Stock	—	—	B	$30.42
NVAXNovavax Inc	B	D	C	$9.44
REPLReplimune Group, Inc.	—	—	A	$15.80
SLBTSL Science Holding Limited Ordinary Shares	—	—	F	$2.64
MGTXMeiraGTx Holdings plc Ordinary Shares	D	C	A	$14.92
VORVor Biopharma Inc. Common Stock	—	—	B	$24.01
CGEMCullinan Therapeutics, Inc. Common Stock	—	—	A	$22.95
IMTXImmatics N.V. Ordinary Shares	C	D	C	$9.24
ODTXOdyssey Therapeutics, Inc. Common Stock	—	C	A	$26.23

About Creative Medical Technology Holdings, Inc. Common Stock

Creative Medical Technology Holdings Inc is a biotechnology company developing therapeutic applications of amniotic fluid-derived stem cells for regenerative medicine. The company targets reproductive and sexual health disorders, including male and female sexual dysfunction, infertility, and miscarriage-related conditions. Its business model centers on creating and licensing intellectual property in this specialized stem cell therapy space.